ArticleHepatology (Baltimore, Md.)2010
Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope.
Article in Hepatology (Baltimore, Md.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 62 citations in OpenAlex.
- Targets of protective immunity and opportunities in hepatitis C virus vaccine development.Nature reviews. Immunology · 2026Review
- HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity.Nature reviews. Rheumatology · 2025Review
- Immunogenetics of longevity and its association with human endogenous retrovirus K.Frontiers in aging · 2025Article
- HLA Class I (A and B) Allele Polymorphism in a Moroccan Population Infected with Hepatitis C Virus.Current issues in molecular biology · 2024Article
- Uncovering Resistance to Hepatitis C Virus Infection: Scientific Contributions and Unanswered Questions in the Irish Anti-D Cohort.Pathogens (Basel, Switzerland) · 2022Review
- Adaptive Immune Response against Hepatitis C Virus.International journal of molecular sciences · 2020Review
- HLA-B*27:05 alters immunodominance hierarchy of universal influenza-specific CD8+ T cells.PLoS pathogens · 2020Article
- Viruses Teaching Immunology: Role of LCMV Model and Human Viral Infections in Immunological Discoveries.Viruses · 2019Review
- Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.Gastroenterology · 2019Review
- Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8Journal of virology · 2018Article
- HLA-B, HLA-C and KIR improve the predictive value of IFNL3 for Hepatitis C spontaneous clearance.Scientific reports · 2018Article
- Article
- CD8F1000Research · 2018Review
- The Importance of Understanding MHC-I Diversity in Nonhuman Primate Models of Human Infectious Diseases.Toxicologic pathology · 2017Review
- Tracking TCRβ Sequence Clonotype Expansions during Antiviral Therapy Using High-Throughput Sequencing of the Hypervariable Region.Frontiers in immunology · 2016Article
- The interaction of genetic determinants in the outcome of HCV infection: evidence for discrete immunological pathways.Tissue antigens · 2015Article
- Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection.Gut · 2015Article
- Mutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections.Medical microbiology and immunology · 2015Review
- HLA Preferences for Conserved Epitopes: A Potential Mechanism for Hepatitis C Clearance.Frontiers in immunology · 2015Article
- Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells.Journal of virology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 7 institutions in 4 countries.
Funding
Abstract
unlabelledHuman leukocyte antigen B27 (HLA-B27) is associated with protection in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. This protective role is linked to single immunodominant HLA-B27-restricted CD8+ T-cell epitopes in both infections. In order to define the relative contribution of a specific HLA-B27-restricted epitope to the natural course of HCV infection, we compared the biological impact of the highly conserved HCV genotype 1 epitope, for which the protective role has been described, with the corresponding region in genotype 3 that differs in its sequence by three amino acid residues. The genotype 3a peptide was not recognized by CD8+ T cells specific for the genotype 1 peptide. Furthermore, patients with acute or chronic infection with HCV genotype 3a did not mount T-cell responses to this epitope region, and their autologous viral sequences showed no evidence of T-cell pressure. Finally, we found a significantly higher frequency of HLA-B27 positivity in patients with chronic HCV genotype 3a infection compared to genotype 1 infection, indicating that there is no protection by HLA-B27 in HCV genotype 3 infection.
conclusionOur data indicate that the protective effect of HLA-B27 is limited to HCV genotype 1 infection and does not expand to other genotypes such as genotype 3a. This can most likely be explained by intergenotype sequence diversity leading to the loss of the immunodominant HLA-B27 epitope in viral strains other than genotype 1. Our results underline the central role of a single HLA-B27-restricted epitope-specific CD8+ T-cell response in mediating protection in HCV genotype 1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.